Evidence map›Paper›PMID 34971427›Full record

ArticleCellular and molecular life sciences : CMLS2021

Modified horseshoe crab peptides target and kill bacteria inside host cells.

Anna S Amiss, Jessica B von Pein, Jessica R Webb, Nicholas D Condon, Peta J Harvey, Minh-Duy Phan, Mark A Schembri, Bart J Currie, Matthew J Sweet, David J Craik and 3 more

Open access · greenAbstract read
In one paragraph

Article in Cellular and molecular life sciences : CMLS, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Transcriptomic Signature of Horseshoe CrabCurrent issues in molecular biology · 2022
    Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 2 countries.

Anna S AmissInstitute for Molecular Bioscience, Australian Research Council Centre of Excellence for Innovations in Peptide and Protein Science, The University of Queensland, Brisbane, QLD, 4072, Australia.ORCID http://orcid.org/0000-0002-5365-875X
Jessica B von PeinInstitute for Molecular Bioscience, IMB Centre for Inflammation and Disease Research and Australian Infectious Diseases Research Centre, The University of Queensland, Brisbane, QLD, 4072, Australia.ORCID http://orcid.org/0000-0002-7233-7177
Jessica R WebbGlobal and Tropical Health Division, Menzies School of Health Research, Darwin, NT, 0811, Australia.ORCID http://orcid.org/0000-0002-6332-039X
Nicholas D CondonAustralian Cancer Research Foundation/Institute for Molecular Bioscience Cancer Biology Imaging Facility, The University of Queensland, Brisbane, QLD, 4072, Australia.ORCID http://orcid.org/0000-0002-1833-1129
Peta J HarveyInstitute for Molecular Bioscience, Australian Research Council Centre of Excellence for Innovations in Peptide and Protein Science, The University of Queensland, Brisbane, QLD, 4072, Australia.ORCID http://orcid.org/0000-0003-4735-6242
Minh-Duy PhanSchool of Chemistry and Molecular Biosciences and Australian Infectious Diseases Research Centre, The University of Queensland, Queensland, Australia.ORCID http://orcid.org/0000-0002-3426-1044
Mark A SchembriSchool of Chemistry and Molecular Biosciences and Australian Infectious Diseases Research Centre, The University of Queensland, Queensland, Australia.ORCID http://orcid.org/0000-0003-4863-9260
Bart J CurrieGlobal and Tropical Health Division, Menzies School of Health Research, Darwin, NT, 0811, Australia.ORCID http://orcid.org/0000-0002-8878-8837
Matthew J SweetInstitute for Molecular Bioscience, IMB Centre for Inflammation and Disease Research and Australian Infectious Diseases Research Centre, The University of Queensland, Brisbane, QLD, 4072, Australia.ORCID http://orcid.org/0000-0002-0406-8139
David J CraikInstitute for Molecular Bioscience, Australian Research Council Centre of Excellence for Innovations in Peptide and Protein Science, The University of Queensland, Brisbane, QLD, 4072, Australia.ORCID http://orcid.org/0000-0003-0007-6796
Ronan KapetanovicInstitute for Molecular Bioscience, IMB Centre for Inflammation and Disease Research and Australian Infectious Diseases Research Centre, The University of Queensland, Brisbane, QLD, 4072, Australia. ronan.kapetanovic@fmi.ch.ORCID http://orcid.org/0000-0002-2908-1014
Sónia Troeira HenriquesInstitute for Molecular Bioscience, Australian Research Council Centre of Excellence for Innovations in Peptide and Protein Science, The University of Queensland, Brisbane, QLD, 4072, Australia. sonia.henriques@qut.edu.au.ORCID http://orcid.org/0000-0001-9564-9651
Nicole LawrenceInstitute for Molecular Bioscience, Australian Research Council Centre of Excellence for Innovations in Peptide and Protein Science, The University of Queensland, Brisbane, QLD, 4072, Australia. n.lawrence@imb.uq.edu.au.ORCID http://orcid.org/0000-0002-9013-1770
The University of Queensland · AUAustralian Research Council · AUMenzies School of Health Research · AUAustralian Cancer Research Foundation · AUTranslational Research Institute · AU

Funding

australian government scholarships Reesearch Training Program Scholarshipaustralian research council CE200100012australian research council FL150100146australian research council FT150100398chan zuckerberg initiative 2020-225648national health and medical resarch council 1183927national health and medical research council 1098337
6 · The paper itself

Abstract

Bacteria that occupy an intracellular niche can evade extracellular host immune responses and antimicrobial molecules. In addition to classic intracellular pathogens, other bacteria including uropathogenic Escherichia coli (UPEC) can adopt both extracellular and intracellular lifestyles. UPEC intracellular survival and replication complicates treatment, as many therapeutic molecules do not effectively reach all components of the infection cycle. In this study, we explored cell-penetrating antimicrobial peptides from distinct structural classes as alternative molecules for targeting bacteria. We identified two β-hairpin peptides from the horseshoe crab, tachyplesin I and polyphemusin I, with broad antimicrobial activity toward a panel of pathogenic and non-pathogenic bacteria in planktonic form. Peptide analogs [I11A]tachyplesin I and [I11S]tachyplesin I maintained activity toward bacteria, but were less toxic to mammalian cells than native tachyplesin I. This important increase in therapeutic window allowed treatment with higher concentrations of [I11A]tachyplesin I and [I11S]tachyplesin I, to significantly reduce intramacrophage survival of UPEC in an in vitro infection model. Mechanistic studies using bacterial cells, model membranes and cell membrane extracts, suggest that tachyplesin I and polyphemusin I peptides kill UPEC by selectively binding and disrupting bacterial cell membranes. Moreover, treatment of UPEC with sublethal peptide concentrations increased zinc toxicity and enhanced innate macrophage antimicrobial pathways. In summary, our combined data show that cell-penetrating peptides are attractive alternatives to traditional small molecule antibiotics for treating UPEC infection, and that optimization of native peptide sequences can deliver effective antimicrobials for targeting bacteria in extracellular and intracellular environments.

Indexed as

AnimalsAnti-Bacterial AgentsAntimicrobial Cationic PeptidesAntimicrobial PeptidesBacteriaBacterial InfectionsBone Marrow CellsCell MembraneCells, CulturedDNA-Binding ProteinsErythrocytesHorseshoe CrabsHumansMiceMice, Inbred C57BLPeptides, CyclicAnti-Bacterial AgentsAntimicrobial Cationic PeptidesAntimicrobial PeptidesDNA-Binding ProteinsPeptides, Cyclicpolyphemusin Itachyplesin peptide, Tachypleus tridentatusAntimicrobial peptideHost defenceIntracellular nicheMacrophagesSelective membrane-active mechanismUropathogenic Escherichia coli

Identifiers

PMID34971427
PMCPMC11071844
OpenAlexW4205365761

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.